Manufacturing of life-enhancing medicines boosted by new government funding

22 Nov 2018

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Patients could soon receive faster treatment thanks to a multimillion pound government boost to streamline the production of medicines and treatments, including those used to treat blood cancers and inherited disorders.

Manufacturing of life-enhancing medicines boosted by new government funding

Companies in Northumberland, Oxford and London will adopt new digital technologies, such as artificial intelligence, to support the manufacture of next-generation medicines and treatments.

The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.

Life Sciences Minister Lord Henley said: "New technology can help us live longer, healthier lives and the new projects announced today will improve the speed and accuracy with which medicines get to the people that need them.

"Advances in technology can help us address the challenges that an ageing society presents and we are backing the technologies of tomorrow in our modern Industrial Strategy, with the biggest increase in public research and development investment in UK history."

The three individual projects are:

  • Arc Trinova in Northumberland will use new technologies to speed up the process of the production of patient-specific medicines; it is currently a timely process dispensing individual doses from bulk because of the careful handling, labelling and batch release processes.
  • Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.
  • Autolus in London will look to avoid mix-ups of complex medicines on the supply chain by developing a computer-based system that will constantly monitor the operation, making adjustments to timing, co-ordination and production where necessary, improving the efficiency of the whole system and working at a pace that human operators cannot imitate.
  • One year on from the launch of the Industrial Strategy, this £7.3 million investment is the latest commitment from the £180 million Industrial Strategy Challenge Fund (ISCF) dedicated to leading-edge Medicines Manufacturing.

    Taking steps to improve patient access to life-saving treatments and medicines, Advanced Therapy Treatment Centres, working across the UK, will support the roll-out of cell and gene therapies as clinical trials show them to be safe and cost-effective. The centres bring together expert clinicians, researchers, scientists, developers and private companies to demonstrate how the therapies have impact on patients’ lives.

    Advanced therapies, including cell and gene therapies, represent the next generation of therapies that have the potential to offer treatments for a number of conditions including some blood cancers and inherited conditions for which there are currently limited treatment options.

    UK Research and Innovation (UKRI) is responsible for managing the Industrial Strategy Challenge Fund, which funds the winners of the Medicines Manufacturing Challenge.

    Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: "The projects announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing."

    Read More

    Related news

    New gene therapy manufacturing facility for Orchard Therapeutics

    New gene therapy manufacturing facility for Orchard Therapeutics

    13 Dec 2018

    Enhances company's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale.

    Read more 
    WuXi AppTec expands site in California for pharmaceutical R&D services

    WuXi AppTec expands site in California for pharmaceutical R&D services

    13 Dec 2018

    Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.

    Read more 
    Cambrex expands analytical capabilities

    Cambrex expands analytical capabilities

    12 Dec 2018

    The $1 million investment will assist in getting new products to commercial launch faster.

    Read more 
    Future-oriented packaging concepts from Sanner

    Future-oriented packaging concepts from Sanner

    11 Dec 2018

    Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.

    Read more 
    One month on: medical cannabis is still taboo despite change in law

    One month on: medical cannabis is still taboo despite change in law

    11 Dec 2018

    Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

    Read more 
    SGS to expand bioanalytical testing capabilities

    SGS to expand bioanalytical testing capabilities

    10 Dec 2018

    The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.

    Read more 
    MIT engineers repurpose wasp venom as an antibiotic drug

    MIT engineers repurpose wasp venom as an antibiotic drug

    9 Dec 2018

    Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.

    Read more 
    Spanish CDMO working ahead of EU serialisation deadline

    Spanish CDMO working ahead of EU serialisation deadline

    6 Dec 2018

    Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

    Read more 
    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    5 Dec 2018

    The financing will power the global commercial launch of the company's Fluidity One system.

    Read more 
    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    4 Dec 2018

    The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

    Read more